In a large population-based case-control study, DM2 was a risk factor for BE, independent of obesity and other risk factors. These data suggest that metabolic pathways related to DM2 should be explored in BE pathogenesis and esophageal carcinogenesis (Clinical Gastroenterology and Hepatology)